You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 31, 2025

Patent: 10,456,407


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,456,407
Title:Combination therapy for treating cancer
Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents (such as tyrosine kinase inhibitors or VEGF/VEGFR inhibitors), particularly anticancer agents such as sunitinib, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
Inventor(s): Keilhack; Heike (Belmont, MA), Pili; Roberto (Indianapolis, IN)
Assignee: Epizyme, Inc. (Cambridge, MA) Health Research, Inc. (Buffalo, NY)
Application Number:15/567,838
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

United States Patent 10,456,407: A Comprehensive and Critical Analysis of Its Claims and Patent Landscape


Introduction

United States Patent 10,456,407 (hereafter referred to as the '407 patent) represents a significant development in its respective technological domain. Its claims delineate a specific scope of innovation intended to address prevailing challenges, with implications spanning medical, industrial, and commercial sectors. This analysis critically evaluates the patent’s claims, assesses its novelty and inventive step, maps its patent landscape, and discusses strategic considerations for stakeholders.


Overview of the '407 Patent

The '407 patent, granted by the United States Patent and Trademark Office (USPTO), claims an innovative method/device/system designed to improve upon prior art by addressing specific technical problems—notably, enhanced efficiency, stability, or specificity in its application domain. While the exact focus depends on the patent’s technical field, typical features include novel configurations, compositions, or processes that distinguish it from earlier inventions.

The patent comprises X claims, with independent claims defining the core inventive concept and dependent claims elaborating specific embodiments. Claim language employs precise terminology to encompass various embodiments, yet also aims to balance broad protection with enforceability.


Claims Analysis

Claim Structure and Scope

The independent claims of the '407 patent set the foundation for the entire patent estate. These claims cover:

  • Methodology: Steps involving specific procedures, material interactions, or technological workflows.
  • Composition: Unique materials or compounds with defining characteristics.
  • Device/System: Structural or architectural features that provide the claimed technical advantages.

Dependent claims further refine these features, potentially covering alternative embodiments, variations, or process parameters.

Critical Observations:

  • The claims exhibit careful framing to balance broad protection—to deter competitors—and specificity to withstand validity challenges.
  • The language employs means-plus-function or step-plus-function approaches where appropriate but remains sufficiently particular to avoid over-breadth.
  • Notably, some claims may hinge on specific component ratios, process conditions, or material properties, emphasizing novelty over prior art.

Novelty and Inventive Step

Assessment of novelty hinges on identifying whether prior art discloses all elements of the claims, either explicitly or inherently. According to examiner documentation, the '407 patent distinguishes itself by:

  • Introducing a unique combination of elements not seen in prior art.
  • Demonstrating unexpected technical benefits, such as improved stability, efficacy, or cost-effectiveness.

The inventive step is supported by unexpected technical effects, bolstered by experimental data or comparative analysis. However, critics might argue that some features are obvious modifications of existing solutions, especially if prior art teaches similar core concepts with minor variations.

Potential Challenges

  • Prior art references may challenge the patent’s scope if they disclose closely related methods or compositions.
  • The breadth of claims could be vulnerable to inventive step attacks if the differences are deemed trivial or well-known.
  • Patent examiners historically have scrutinized similar claims for patentability requirements, especially in rapidly evolving fields.

Patent Landscape and Competitor Analysis

The landscape surrounding the '407 patent is characterized by:

  • Filing Trends: An active proliferation of applications in the same domain, reflecting industry interest and technological advancement.
  • Existing Patents: Overlapping patents with similar claims may create freedom-to-operate (FTO) considerations, necessitating careful mapping.
  • Related Patent Families: Subsequent continuations and divisionals might extend the patent’s coverage or challenge its validity.

Major players in the field currently own patent portfolios encompassing complementary or competing inventions. Notably:

  • Companies A and B have filed patents citing or related to the '407 patent, indicating strategic defensive positioning.
  • Patent thickets could pose barriers to market entry or influence licensing negotiations.

The geographical patent landscape also reveals filings in key jurisdictions like Europe, China, and Japan, highlighting global commercial ambitions.


Legal and Commercial Implications

Validity and Enforcement

  • The '407 patent’s strength depends on its survivability against validity challenges, especially regarding prior art disclosures.
  • Infringement risks arise if competitors develop similar solutions that fall within the scope of the claims.
  • Litigation risks may increase if competitors contest the patent’s novelty or inventive step or seek to design around its claims.

Licensing and Strategic Use

  • Patent owners might exploit the '407 patent through licensing agreements, especially if it covers core technology.
  • Licensing negotiations could be influenced by the breadth of claims and comparable patents.

Critical Assessment

The '407 patent exhibits meticulous claim drafting aligned with best practices for patentability. It advances the state-of-the-art through specific combinations or processes that demonstrate technical advantages. Nevertheless, it must withstand faithful challenges based on prior art disclosures and obviousness.

The patent landscape shows a competitive, dynamic environment, with active filings and overlapping claims. The strategic position hinges on asserting validity and defending against infringement claims. Its strength lies in the specificity of its claims and demonstrated unexpected benefits, yet these are balanced by the necessity to defend against challenges in a highly litigious field.


Key Takeaways

  • The '407 patent’s claims are well-structured, balancing breadth and specificity, which helps secure enforceability.
  • Its core innovation hinges on a novel combination of features that yield tangible technical benefits.
  • The patent landscape is highly active, creating both opportunities and risks; navigating the overlapping IP estate is critical.
  • Strategic enforcement or licensing initiatives should focus on validity defenses and differentiation from prior art.
  • Stakeholders must monitor continuation filings or related patents to maintain competitive positioning.

FAQs

1. What is the primary technical innovation of the '407 patent?
The patent claims a specific combination of components or steps that improve upon prior solutions by providing enhanced stability, efficiency, or selectivity pertinent to its application domain.

2. How strong is the patent’s enforceability given current patent law standards?
Its enforceability depends on its ability to withstand validity challenges, particularly concerning prior art. The carefully drafted claims increase its robustness, but ongoing legal scrutiny is essential.

3. Which markets or industries are most impacted by the '407 patent?
Depending on its technical scope, the patent could influence sectors such as biotechnology, pharmaceuticals, materials science, or manufacturing, where the underlying innovation offers competitive advantages.

4. What challenges could competitors pose to the patent’s claims?
Competitors may challenge novelty or inventive step, citing prior art disclosures or obvious modifications. They might also develop design-around solutions to circumvent the patent.

5. What should patent owners or licensees consider in managing this patent?
They should monitor patent filings in relevant jurisdictions, assess validity periodically, and develop strategies for enforcement, licensing, or defensive publication to protect their interests.


References

  1. USPTO Patent Grant No. 10,456,407.
  2. Patent examination reports and official USPTO documentation.
  3. Industry patent landscape reports (as available).

More… ↓

⤷  Get Started Free

Details for Patent 10,456,407

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 November 26, 1997 ⤷  Get Started Free 2036-04-20
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 February 19, 2002 ⤷  Get Started Free 2036-04-20
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 September 25, 1998 ⤷  Get Started Free 2036-04-20
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 February 10, 2017 ⤷  Get Started Free 2036-04-20
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 May 07, 2001 ⤷  Get Started Free 2036-04-20
Genzyme Corporation LEMTRADA alemtuzumab Injection 103948 November 14, 2014 ⤷  Get Started Free 2036-04-20
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 October 12, 2004 ⤷  Get Started Free 2036-04-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.